{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T22:35:43Z","timestamp":1776119743428,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":157,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018353","name":"European Crohn's and Colitis Organisation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018353","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","award":["CA 18133"],"award-info":[{"award-number":["CA 18133"]}],"id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004770","name":"Universit\u00e0 degli Studi di Parma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004770","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.ejphar.2023.175613","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T08:21:04Z","timestamp":1677226864000},"page":"175613","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Probing the effects of MR120 in preclinical chronic colitis: A first-in-class anti-IBD agent targeting the CCL20\/CCR6 axis"],"prefix":"10.1016","volume":"945","author":[{"given":"Marika","family":"Allodi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmine","family":"Giorgio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Incerti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Corradi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Flammini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vigilio","family":"Ballabeni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Barocelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0874-6697","authenticated-orcid":false,"given":"Marco","family":"Radi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Bertoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2023.175613_bib1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/ibd.20753","article-title":"Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis","volume":"15","author":"Alex","year":"2009","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.ejphar.2023.175613_bib2","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1046\/j.1365-2036.1998.00357.x","article-title":"Experimental colitis induced by dextran sulphate sodium in mice: beneficial effects of sulphasalazine and olsalazine","volume":"12","author":"Axelsson","year":"1998","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2023.175613_bib3","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.bcp.2012.09.007","article-title":"Evaluation of chemical mediators and cellular response during acute and chronic gut inflammatory response induced by dextran sodium sulfate in mice","volume":"84","author":"Bento","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.175613_bib4","first-page":"207","article-title":"Experimental colitis induced by dextran sulphate in normal and germfree mice","volume":"7","author":"Bylund-Fellenius","year":"1994","journal-title":"Microb. Ecol. Health Dis."},{"key":"10.1016\/j.ejphar.2023.175613_bib5","first-page":"238","article-title":"Clinicopathologic study of dextran sulfate sodium experimental murine colitis","volume":"69","author":"Cooper","year":"1993","journal-title":"Lab. Invest."},{"key":"10.1016\/j.ejphar.2023.175613_bib6","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3390\/ph14060502","article-title":"UniPR1331: small eph\/ephrin antagonist beneficial in intestinal inflammation by interfering with type-B signaling","volume":"14","author":"Giorgio","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejphar.2023.175613_bib7","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3389\/fphar.2017.00809","article-title":"\u03b17 nicotinic agonist AR-r17779 protects mice against 2,4,6-trinitrobenzene sulfonic acid-induced colitis in a spleen-dependent way","volume":"8","author":"Grandi","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.175613_bib8","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1172\/JCI117974","article-title":"Neutrophil chemoattractants generated in two phases during reperfusion of ischemic myocardium in the rabbit. Evidence for a role for C5a and interleukin-8","volume":"95","author":"Ivey","year":"1995","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2023.175613_bib9","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1023\/B:JOCI.0000018066.46279.6b","article-title":"Increased expression of CCL20 in human inflammatory bowel disease","volume":"24","author":"Kaser","year":"2004","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.ejphar.2023.175613_bib10","doi-asserted-by":"crossref","first-page":"G1263","DOI":"10.1152\/ajpgi.00409.2006","article-title":"MIP-3alpha neutralizing monoclonal antibody protects against TNBS-induced colonic injury and inflammation in mice","volume":"292","author":"Katchar","year":"2007","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.ejphar.2023.175613_bib11","article-title":"Evaluation of the relationship between the spleen volume and the disease activity in ulcerative colitis and Crohn disease","volume":"101","author":"Kawashima","year":"2022","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.ejphar.2023.175613_bib12","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1189\/jlb.1RU0716-327R","article-title":"Role of chemokine receptors and intestinal epithelial cells in the mucosal inflammation and tolerance","volume":"101","author":"Kulkarni","year":"2017","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.ejphar.2023.175613_bib13","article-title":"Isolation of mouse mononuclear cells","author":"Kruisbeek","year":"2001","journal-title":"Curr. Protoc. Im."},{"key":"10.1016\/j.ejphar.2023.175613_bib14","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3389\/fimmu.2013.00194","article-title":"CC chemokine ligand 20 and its cognate receptor CCR6 in mucosal T cell immunology and inflammatory bowel disease: odd couple or Axis of evil?","volume":"4","author":"Lee","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2023.175613_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114703","article-title":"Discovery of small-molecules targeting the CCL20\/CCR6 axis as first-in-class inhibitors for inflammatory bowel diseases","volume":"243","author":"Martina","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejphar.2023.175613_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102846","article-title":"CCR6-CCL20 axis as a therapeutic target for autoimmune diseases","volume":"20","author":"Meitei","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.ejphar.2023.175613_bib17","first-page":"258","article-title":"Ischemic preconditioning protects against gut dysfunction and mucosal injury after ischemia\/reperfusion injury","volume":"23","author":"Moore-Olufemi","year":"2005","journal-title":"Shock"},{"key":"10.1016\/j.ejphar.2023.175613_bib18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nri3661","article-title":"Cytokines in inflammatory bowel disease","volume":"14","author":"Neurath","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejphar.2023.175613_bib19","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/1521-4141(200105)31:5<1465::AID-IMMU1465>3.0.CO;2-E","article-title":"Characterization of chemokines and chemokine receptors in two murine models of inflammatory bowel disease: IL-10-\/- mice and Rag-2-\/- mice reconstituted with CD4+CD45RBhigh T cells","volume":"31","author":"Scheerens","year":"2001","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ejphar.2023.175613_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141710","article-title":"Expression of CCL20 and its corresponding receptor CCR6 is enhanced in active inflammatory bowel disease, and TLR3 mediates CCL20 expression in colonic epithelial cells","volume":"10","author":"Skovdahl","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2023.175613_bib21","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.3390\/ijms19103257","article-title":"C-C motif ligand 20 (CCL20) and C-C motif chemokine receptor 6 (CCR6) in human peripheral blood mononuclear cells: dysregulated in ulcerative colitis and a potential role for CCL20 in IL-1\u03b2 release","volume":"19","author":"Skovdahl","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2023.175613_bib22","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2249.2004.02716.x","article-title":"Increased lymphocyte trafficking to colonic microvessels is dependent on MAdCAM-1 and C-C chemokine mLARC\/CCL20 in DSS-induced mice colitis","volume":"139","author":"Teramoto","year":"2005","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ejphar.2023.175613_bib23","doi-asserted-by":"crossref","first-page":"S641","DOI":"10.1093\/ecco-jcc\/jjx145","article-title":"Chemokines and chemokine receptors as therapeutic targets in inflammatory bowel disease; pitfalls and promise","volume":"12","author":"Trivedi","year":"2018","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.ejphar.2023.175613_bib24","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ejphar.2015.03.017","article-title":"Experimental colitis models: insights into the pathogenesis of inflammatory bowel disease and translational issues","volume":"759","author":"Valatas","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.175613_bib25","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1002\/eji.200324347","article-title":"CCR6 has a non-redundant role in the development of inflammatory bowel disease","volume":"33","author":"Varona","year":"2003","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ejphar.2023.175613_bib26","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.tetlet.2016.02.068","article-title":"A microwave-assisted multicomponent protocol for the synthesis of benzofuran-2-carboxamides","volume":"57","author":"Vincetti","year":"2016","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ejphar.2023.175613_bib27","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/labinvest.2013.89","article-title":"Protective role of tumor necrosis factor (TNF) receptors in chronic intestinal inflammation: TNFR1 ablation boosts systemic inflammatory response","volume":"93","author":"Wang","year":"2013","journal-title":"Lab. Invest."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923001243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923001243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T23:15:25Z","timestamp":1757978125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299923001243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":27,"alternative-id":["S0014299923001243"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.175613","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Probing the effects of MR120 in preclinical chronic colitis: A first-in-class anti-IBD agent targeting the CCL20\/CCR6 axis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.175613","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"175613"}}